Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D, et al. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis. 1 déc 2003;37(11):1517‑26. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/14614675
Chêne G, Sterne JAC, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (London, England). 30 août 2003;362(9385):679‑86. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/12957089
Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 15 sept 2003;21(18):3447‑53. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/12972519
Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D, et al. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 1 sept 2003;34(1):50‑7. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/14501793
Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 21 nov 2003;17(17):2479‑86. Disponible sur: http://www.ncbi.nlm.nih.gov/pubmed/14600519
